A Randomized, Double-Blind, Placebo- Controlled Study to Investigate the Efficacy and Safety of Injectafer (Ferric Carboxymaltose) as Treatment for Heart Failure With Iron Deficiency
Latest Information Update: 15 Jul 2024
At a glance
- Drugs Ferric carboxymaltose (Primary)
- Indications Iron deficiency anaemia
- Focus Registrational; Therapeutic Use
- Acronyms HEART-FID
- Sponsors American Regent; Luitpold Pharmaceuticals
- 08 Apr 2024 Results assessing all cause mortality in HEART-FID trial presented at the 73rd Annual Scientific Session of the American College of Cardiology.
- 08 Apr 2024 Results (n=133) from a prespecified substudy of HEART-FID presented at the 73rd Annual Scientific Session of the American College of Cardiology.
- 19 Mar 2024 According to a CSL Vifor media release, company announced that Health Canada has authorized Ferinject (ferric carboxymaltose) for the intravenous (IV) treatment of iron deficiency anemia in adult and pediatric patients one year of age and older when oral iron preparations are not tolerated or are ineffective, as well as for the treatment of iron deficiency in adult patients with heart failure and New York Heart Association (NYHA) class II/III to improve exercise capacity.